SLC5A2 and hydrops fetalis: In recent large, placebo-controlled trials of SGLT2 inhibitors and other prospective studies concerning the heart and kidney during short observation periods, the prominent desirable effect on HF, albuminuria, and decrease in GFR were clarified.